7502-05-8

Upstream product

• 92-91-1 biphenyl-4-acetaldehyde 
• 773837-37-9 sodium cyanide 
• 92-52-4 biphenyl 
• 151-50-8 potassium cyanide 

Downstream Products

• 1031394-16-7 5-([1,1'-biphenyl]-4-yl)-3-(4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-n-propylphenoxy)butyl)-5-methylimidazolidine-2,4-dione 
• 1031395-90-0 5-([1,1'-biphenyl]-4-yl)-3-(4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2,6-di-n-propylphenoxy)butyl)-5-methylimidazolidine-2,4-dione 

Relevant academic research and scientific papers

Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists

A novel series of 1,3-bistrifluoromethylcarbinol derivatives that act as liver X receptor (LXR) β-selective agonists was discovered. Structure-activity relationship studies led to the identification of molecule 62, which was more effective (Emax) and selective toward LXRβ than T0901317 and GW3965. Furthermore, 62 decreased LDL-C without elevating the plasma TG level and significantly suppressed the lipid-accumulation area in the aortic arch in a Bio F1B hamster fed a diet high in fat and cholesterol. We demonstrated that our LXRβ agonist would be potentially useful as a hypolipidemic and anti-atherosclerotic agent. In this manuscript, we report the design, synthesis and pharmacology of 1,3-bistrifluoromethylcarbinol derivatives.